BIMERVAX®, emulsion for injection
BIMERVAX®, COVID-19 adjuvanted recombinant protein vaccine.
Marketing authorization in the European Union since 30 March 2023 and in the United Kingdom since 31 July 2023.
Update date: 18/06/24
The use of this vaccine should be according official recommendations.
PRESENTATIONS of BIMERVAX emulsion for injection:
· Multidose vial which contains 10 doses of 0.5 mL
· Single dose vial which contains 1-dose of 0.5 Ml
PRESCRIPTION AND DISPENSING CONDITIONS. Medicinal product subject to medical prescription. Dispensing should be conducted in health care sites.
PRICE (PVL): . Not included in the pharmaceutical provision of the National Health System due to the fact that the acquisition of this vaccine against SARS-CoV-2 is being carried out in the European Union by means of a centralised European purchasing procedure, conducted by the European Commission on behalf of the Member States.
This medicine is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are invited to report suspected adverse reactions.